Prometheus Laboratories Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of ProleukinÂ® (Aldesleukin for Injection) and YervoyÂ® (Ipilimumab) in Patients with Metastatic Melanoma